These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22946342)

  • 21. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring therapeutic monoclonal antibodies in brain tumor.
    Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
    MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
    Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
    J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
    Clark AJ; Lamborn KR; Butowski NA; Chang SM; Prados MD; Clarke JL; McDermott MW; Parsa AT; Berger MS; Aghi MK
    Neurosurgery; 2012 Feb; 70(2):361-70. PubMed ID: 21841523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.
    Quillien V; Carpentier AF; Gey A; Avril T; Tartour E; Sejalon F; Campillo-Gimenez B; Vauleon E
    Cancer Immunol Immunother; 2019 Jun; 68(6):871-882. PubMed ID: 30830269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption in patients with recurrent malignant gliomas: case report and literature review].
    Kaprin AD; Zaitsev AM; Rerberg AG; Fedenko AA; Datsenko PV; Kirsanova ON
    Zh Vopr Neirokhir Im N N Burdenko; 2021; 85(5):64-70. PubMed ID: 34714005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurosurgeons achieve world's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Future Oncol; 2010 Jan; 6(1):9. PubMed ID: 20021203
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
    de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
    Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
    Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
    Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A murine model of targeted infusion for intracranial tumors.
    Kim M; Barone TA; Fedtsova N; Gleiberman A; Wilfong CD; Alosi JA; Plunkett RJ; Gudkov A; Skitzki JJ
    J Neurooncol; 2016 Jan; 126(1):37-45. PubMed ID: 26376657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
    Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
    Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.
    Yang SH; Hong YK; Jeun SS; Kim IS; Hong JT; Sung JH; Son BC; Lee SW; Kim MC; Lee KS
    J Neurooncol; 2009 Oct; 95(1):23-28. PubMed ID: 19381443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
    Kumar K; Wigfield S; Gee HE; Devlin CM; Singleton D; Li JL; Buffa F; Huffman M; Sinn AL; Silver J; Turley H; Leek R; Harris AL; Ivan M
    J Mol Med (Berl); 2013 Jun; 91(6):749-58. PubMed ID: 23361368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
    Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
    Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
    Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.